[ad_1] STOCKHOLM, Oct. 30, 2024 /PRNewswire/ — Sobi® (STO: SOBI) today announced that new research showing the effect of emapalumab in patients with macrophage activation syndrome (MAS) in Still’s disease, including systemic juvenile idiopathic arthritis […]
Tag: Swedish Orphan Biovitrum AB
Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN
[ad_1] Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints favoured treatment with pegcetacoplan, including: – Stabilised eGFR, a key measure of kidney function– 71% of patients […]
Strong growth and significant pipeline momentum
[ad_1] STOCKHOLM, Oct. 24, 2024 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2024 Third Quarter 2024 Total revenue increased 33 per cent, 39 per cent at […]
Sobi has completed issues of class C shares
[ad_1] STOCKHOLM, Aug. 29, 2024 /PRNewswire/ — The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 14 May 2024 resolved on directed issues of redeemable and convertible class C shares and to authorise […]
Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN
[ad_1] Met the primary endpoint, achieving statistically significant 68% (p<0.0001) reduction in proteinuria compared to placebo in a broad study population Positive results consistent across all subgroups, including C3G and IC-MPGN, adolescent and adult patients, […]
